Ruby Khoury, Michael S Grimley, Adam S Nelson, Tom Leemhuis, Jose A Cancelas, Eleanor Cook, YunZu Wang, Daria Heyenbruch, Catherine M Bollard, Michael D Keller, Patrick J Hanley, Carolyn Lutzko, Giang Pham, Stella M Davies, Jeremy D Rubinstein
Reactivation or primary infection with double stranded DNA viruses is common in recipients of solid organ transplants and is associated with significant morbidity and mortality. Treatment with conventional anti-viral medications is limited by toxicities, resistance, and lack of effective options for adenovirus and BKPyV. Virus-specific T-cells (VSTs) have been shown to be an effective treatment for infections with adenovirus, BKPyV, cytomegalovirus (CMV), and Epstein-Barr virus (EBV). Most of these studies have been conducted in stem cell recipients and no large studies have been published in the solid organ transplant population to date...
April 19, 2024: American Journal of Transplantation